Key Points
- Thermo Fisher COO Gianluca Pettiti sold 400 shares at $565 each, generating $226,000 in proceeds. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 1.6% to 24,651 shares.
- The company exceeded quarterly expectations, reporting $6.03 in EPS versus the $5.71 consensus estimate and $11.99 billion in revenue versus $11.71 billion expected. Revenue increased 10.5% year over year, and fiscal 2026 EPS guidance was set at $24.93–$25.33.
- Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and a $617.14 price target. Thermo Fisher also declared a quarterly dividend of $0.47 per share, equivalent to a 0.3% annualized yield.
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Thermo Fisher Scientific Trading Up 3.2%
NYSE TMO opened at $577.32 on Wednesday. The firm has a market cap of $214.54 billion, a PE ratio of 31.06, a price-to-earnings-growth ratio of 2.28 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The stock has a 50-day moving average of $498.92 and a 200-day moving average of $512.05. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the company earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.11%.
Wall Street Analysts Forecast Growth
TMO has been the subject of several analyst reports. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research report on Friday, May 8th. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They set a "market perform" rating and a $520.00 price objective for the company. Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 target price on the stock. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. Finally, KeyCorp reiterated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $617.14.
Get Our Latest Stock Report on Thermo Fisher Scientific
Institutional Investors Weigh In On Thermo Fisher Scientific
Several institutional investors and hedge funds have recently modified their holdings of TMO. Merit Financial Group LLC boosted its stake in shares of Thermo Fisher Scientific by 47.9% during the 2nd quarter. Merit Financial Group LLC now owns 21,997 shares of the medical research company's stock valued at $11,028,000 after purchasing an additional 7,125 shares in the last quarter. Diversified Trust Co. lifted its holdings in Thermo Fisher Scientific by 71.1% in the second quarter. Diversified Trust Co. now owns 17,214 shares of the medical research company's stock worth $8,630,000 after buying an additional 7,155 shares during the period. Cary Street Partners Financial LLC boosted its position in Thermo Fisher Scientific by 3.3% during the 2nd quarter. Cary Street Partners Financial LLC now owns 33,339 shares of the medical research company's stock valued at $16,715,000 after acquiring an additional 1,056 shares in the last quarter. Liberty Capital Management Inc. purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $8,524,000. Finally, Baker Tilly Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 43.3% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 1,456 shares of the medical research company's stock worth $730,000 after acquiring an additional 440 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
